• +1-646-491-9876
    • +91-20-67278686

    Search

    Celiac Disease - Pipeline Review, H1 2017

    Celiac Disease - Pipeline Review, H1 2017

    • Report Code ID: RW0001767494
    • Category Pharmaceuticals
    • No. of Pages 82
    • Publication Month Apr-17
    • Publisher Name Global Markets Direct
    Celiac Disease - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Celiac Disease - Pipeline Review, H1 2017, provides an overview of the Celiac Disease (Gastrointestinal) pipeline landscape.

    Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain and persistent diarrhea. Risk factors include lupus, rheumatoid arthritis, type 1 diabetes, autoimmune liver disease, Sjogren's syndrome and Turner syndrome. Treatment includes steroids such as betamethasone and prednisolone. Further the treatment regime also involves adhering to strict gluten free diet

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Celiac Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Celiac Disease (Gastrointestinal) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Celiac Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 10 and 5 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

    Celiac Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Celiac Disease (Gastrointestinal) .
    - The pipeline guide reviews pipeline therapeutics for Celiac Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Celiac Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Celiac Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Celiac Disease (Gastrointestinal)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Celiac Disease (Gastrointestinal) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Celiac Disease (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    List of Tables 4
    List of Figures 4
    Introduction 5
    Publisher Report Coverage 5
    Celiac Disease - Overview 6
    Celiac Disease - Therapeutics Development 7
    Pipeline Overview 7
    Pipeline by Companies 8
    Pipeline by Universities/Institutes 11
    Products under Development by Companies 12
    Products under Development by Universities/Institutes 14
    Celiac Disease - Therapeutics Assessment 15
    Assessment by Target 15
    Assessment by Mechanism of Action 17
    Assessment by Route of Administration 19
    Assessment by Molecule Type 21
    Celiac Disease - Companies Involved in Therapeutics Development 23
    Amgen Inc 23
    Amyra Biotech AG 23
    Calypso Biotech SA 24
    Circle33 LLC 24
    enGene Inc 25
    F. Hoffmann-La Roche Ltd 25
    Glenmark Pharmaceuticals Ltd 26
    ImmusanT Inc 26
    Innovate Biopharmaceuticals Inc 27
    Intrexon Corp 27
    Sanofi 28
    Takeda Pharmaceutical Company Ltd 28
    Zedira GmbH 29
    Celiac Disease - Drug Profiles 30
    AMG-714 - Drug Profile 30
    AVX-176 - Drug Profile 32
    Biologic for Celiac Disease - Drug Profile 33
    BNZ-2 - Drug Profile 34
    CALY-002 - Drug Profile 35
    ERW-1041E - Drug Profile 36
    GBR-830 - Drug Profile 37
    Kuma-010 - Drug Profile 38
    larazotide acetate - Drug Profile 39
    latiglutenase - Drug Profile 42
    Monoclonal Antibody to Antagonize IL-2R Beta for Celiac Disease, Tropical Spastic Paraparesis and Oncology - Drug Profile 45
    Nexvax-2 - Drug Profile 46
    Nexvax-3 - Drug Profile 49
    Oligonucleotides for Celiac Disease - Drug Profile 50
    Protein for Celiac Disease - Drug Profile 51
    Recombinant Enzymes to Inhibit Gluten for Celiac Disease - Drug Profile 52
    Recombinant Protein for Celiac Disease - Drug Profile 53
    RG-7625 - Drug Profile 54
    Synthetic Peptides to Inhibit DQ2/DQ8 for Celiac Disease and Type 1 Diabetes - Drug Profile 55
    Vaccine for Celiac Disease - Drug Profile 56
    Vaccine for Celiac Disease - Drug Profile 58
    vedolizumab - Drug Profile 59
    ZED-1227 - Drug Profile 66
    ZED-754 - Drug Profile 67
    Celiac Disease - Dormant Projects 68
    Celiac Disease - Product Development Milestones 69
    Featured News & Press Releases 69
    Appendix 79
    Methodology 79
    Coverage 79
    Secondary Research 79
    Primary Research 79
    Expert Panel Validation 79
    Contact Us 79
    Disclaimer 80

    List of Tables

    Number of Products under Development for Celiac Disease, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Celiac Disease - Pipeline by Amgen Inc, H1 2017
    Celiac Disease - Pipeline by Amyra Biotech AG, H1 2017
    Celiac Disease - Pipeline by Calypso Biotech SA, H1 2017
    Celiac Disease - Pipeline by Circle33 LLC, H1 2017
    Celiac Disease - Pipeline by enGene Inc, H1 2017
    Celiac Disease - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Celiac Disease - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017
    Celiac Disease - Pipeline by ImmusanT Inc, H1 2017
    Celiac Disease - Pipeline by Innovate Biopharmaceuticals Inc, H1 2017
    Celiac Disease - Pipeline by Intrexon Corp, H1 2017
    Celiac Disease - Pipeline by Sanofi, H1 2017
    Celiac Disease - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
    Celiac Disease - Pipeline by Zedira GmbH, H1 2017
    Celiac Disease - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Celiac Disease, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    Amgen Inc
    Amyra Biotech AG
    Calypso Biotech SA
    Circle33 LLC
    enGene Inc
    F. Hoffmann-La Roche Ltd
    Glenmark Pharmaceuticals Ltd
    ImmusanT Inc
    Innovate Biopharmaceuticals Inc
    Intrexon Corp
    Sanofi
    Takeda Pharmaceutical Company Ltd
    Zedira GmbH

    Request for Sample

    Report Url http://www.reportsweb.com//celiac-disease-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//celiac-disease-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//celiac-disease-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments